REVIEW  MICROBIOTA AND DIGESTIVE DISEASES 

Minerva Gastroenterology 2021 December;67(4):348-56

DOI: 10.23736/S2724-5985.21.02909-0

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

Probiotics and obesity associated disease: an extended view beyond traditional strains

Tetyana FALALYEYEVA ¹, Yelyzaveta MAMULA ¹, Emidio SCARPELLINI ², Ivan LESHCHENKO ³, Alla HUMENIUK ³, Ivan PANKIV ⁴, Nazarii KOBYLIAK ^{5, 6} ✉

¹ Institute of Biology and Medicine, Educational and Scientific Center, Taras Shevchenko National University, Kyiv, Ukraine; ² Department of Chronic Diseases, Metabolism and Ageing (ChroMetA), Translational Research Center for Gastrointestinal Disorders (TARGID), Catholic University, Leuven, Belgium; ³ Department of Physiology, Bogomolets National Medical University, Kyiv, Ukraine; ⁴ Department of Clinical Immunology, Allergology and Endocrinology, Bukovinian State Medical University, Chernivtsi, Ukraine; ⁵ Department of Endocrinology, Bogomolets National Medical University, Kyiv, Ukraine; ⁶ Medical Laboratory CSD, Kyiv, Ukraine

Interaction between intestinal microbiota and obesity is becoming abundantly according to current many scientific investigations. In this article, probiotic therapy was offered as the promising strategy of metabolic disorders control through the recovery of microbiota composition and health maintenance with the help of impact on the abovementioned mechanisms. First, this therapy is safe, with minimal side effects, well-tolerated, and appropriate for long-term use. Second, it can improve body mass, glucose, and fat metabolism, increase insulin sensitivity, and decrease systemic chronic inflammation. In conclusion, the restorative role of gut microbiota on metabolic disorders and associated diseases could open new ways in the treatment of obesity, insulin resistance, and type 2 diabetes.

KEY WORDS: Obesity; Diabetes mellitus, type 2; Non-alcoholic fatty liver disease; Probiotics; Prevotela copri; Akkermansia muciniphila